Tecuro

Executive Summary

Tecuro AG is a Swiss medical technology company founded in 2018 and headquartered in Zug. The company specializes in developing innovative medical devices and drug delivery systems, with a core focus on a proprietary needle-free injection technology for precise and painless liquid drug administration. This technology addresses significant patient pain points such as needle phobia and improves treatment adherence, positioning Tecuro in the growing needle-free injection market. Although the company is in its early stages with limited public financial or operational data, its technology has potential applications across multiple therapeutic areas. Tecuro's success will depend on achieving regulatory clearances and forging partnerships with pharmaceutical companies to integrate its delivery system with existing drugs.

Upcoming Catalysts (preview)

• Q1 2027First-in-Human Clinical Trial Start50% success
• Q4 2026Partnership with Pharma for Drug-Delivery Integration40% success
• Q3 2027CE Mark or FDA Breakthrough Device Designation30% success